Oppenheimer Asset Management Inc. reduced its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 39.0% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 28,059 shares of the biopharmaceutical company’s stock after selling 17,933 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Halozyme Therapeutics were worth $1,072,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also added to or reduced their stakes in the company. B. Metzler seel. Sohn & Co. AG bought a new position in Halozyme Therapeutics during the 1st quarter valued at approximately $1,252,000. Private Advisor Group LLC bought a new position in shares of Halozyme Therapeutics during the first quarter valued at approximately $829,000. LPL Financial LLC lifted its stake in Halozyme Therapeutics by 53.0% in the first quarter. LPL Financial LLC now owns 30,268 shares of the biopharmaceutical company’s stock worth $1,156,000 after acquiring an additional 10,482 shares during the period. Pictet Asset Management SA boosted its holdings in Halozyme Therapeutics by 59.6% in the first quarter. Pictet Asset Management SA now owns 219,804 shares of the biopharmaceutical company’s stock valued at $8,394,000 after acquiring an additional 82,048 shares in the last quarter. Finally, Great Lakes Advisors LLC purchased a new position in Halozyme Therapeutics during the 1st quarter valued at $6,471,000. Hedge funds and other institutional investors own 92.93% of the company’s stock.
Analyst Ratings Changes
HALO has been the subject of several research analyst reports. TheStreet raised shares of Halozyme Therapeutics from a “c+” rating to a “b” rating in a research report on Tuesday, August 8th. StockNews.com upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, August 16th. Piper Sandler raised their target price on Halozyme Therapeutics from $46.00 to $48.00 in a research note on Wednesday, August 9th. The Goldman Sachs Group cut Halozyme Therapeutics from a “buy” rating to a “neutral” rating and upped their price target for the stock from $43.00 to $45.00 in a research note on Monday, July 24th. Finally, HC Wainwright lowered their price objective on Halozyme Therapeutics from $61.00 to $60.00 and set a “buy” rating for the company in a research report on Tuesday, August 15th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $54.27.
Halozyme Therapeutics Stock Performance
Shares of HALO opened at $42.69 on Friday. The company has a market cap of $5.63 billion, a price-to-earnings ratio of 24.96, a P/E/G ratio of 0.65 and a beta of 1.24. The business’s fifty day simple moving average is $40.10 and its two-hundred day simple moving average is $38.64. Halozyme Therapeutics, Inc. has a 12 month low of $29.85 and a 12 month high of $59.46. The company has a current ratio of 6.58, a quick ratio of 5.44 and a debt-to-equity ratio of 9.91.
Insider Activity
In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction dated Wednesday, June 21st. The stock was sold at an average price of $36.00, for a total value of $360,000.00. Following the completion of the transaction, the senior vice president now owns 141,911 shares of the company’s stock, valued at approximately $5,108,796. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold a total of 80,000 shares of company stock valued at $3,345,700 over the last ninety days. 2.40% of the stock is currently owned by corporate insiders.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Recommended Stories
- Five stocks we like better than Halozyme Therapeutics
- 5 Top Rated Dividend Stocks to Consider
- 2 Stocks to Get You Ready for the Holiday Season
- The How and Why of Investing in Biotech Stocks
- Profit Potential: 5 Undervalued Stocks With High Dividend Yields
- How to Invest in the FAANG Stocks
- MarketBeat Week in Review – 8/21 – 8/25
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report).
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
